Treats partial-onset seizures. ANDA 217782, held by Pharmazone. Oxcarbazepine.
As of Nov 16, 2026, ANDA 217782 (Oxcarbazepine), held by Pharmazone, was first approved by FDA on Feb 14, 2024, with 1 approved supplement and 0 published complete response letters.
Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine oral suspension is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4–16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2–16 years
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 14, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxcarbazepine300MG/5ML · suspension;oral | Oxcarbazepine | Rx |
| Jul 13, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 14, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters